奥司他韦
病毒学
药品
医学
病毒复制
抗病毒药物
病毒
甲型流感病毒
临床试验
H5N1亚型流感病毒
病毒载量
药理学
内科学
2019年冠状病毒病(COVID-19)
疾病
传染病(医学专业)
作者
Jordi Reina,Núria Reina
出处
期刊:PubMed
[National Institutes of Health]
日期:2019-02-01
卷期号:32 (1): 1-5
被引量:5
摘要
Baloxavir marboxil (5-hydroxy-4-pyridone-3-carboxyl acid) is a new antiviral drug with special efficacy on influenza viruses that acts by inhibiting the cap-dependent endonuclease required for its replication. It is the first representative of the so-called inhibitors of influenza-like PB2. It has shown efficacy against influenza viruses A and B and most strains of animal origin (avian flu). Clinical trials conducted in healthy patients between 12 and 64 years without pathologies and not hospitalized (mild flu) have shown a reduction in the duration of symptoms similar to that obtained by oseltamivir. However, baloxavir is a much more potent inhibitor of viral replication than this drug. It has been shown as a safe and well tolerated drug. A single dose of 40-80 mg is administered the first 48 hours after onset of symptoms. In these trials, strains with moderate sensitivity (PA / I38T mutants) were detected in 2.2% of influenza A (H1N1) pdm09 and in 9.7% of influenza A (H3N2). Although these data could be a good drug to treat mild or moderate influenza, requiring trials in severe influenza and patients with chronic diseases to establish their true clinical utility.
科研通智能强力驱动
Strongly Powered by AbleSci AI